Lexicon (LXRX) Pharmaceuticals announced that new sotagliflozin clinical data was presented at the American Heart Association, AHA, Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction, HFpEF,, and without diabetes, across a range of measures, including cardiac structure and function, quality of life and functional capacity. Treatment with sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, capacity for a six-minute walk test, and KCCQ measurements. In addition, though peak VO2 improvement did not achieve statistical significance, there was a notable improvement after treatment with sotagliflozin.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals: Promising Developments and Strategic Progress Justify Buy Rating
- Lexicon Pharmaceuticals Reports Strong Q3 2025 Results
- Lexicon Pharmaceuticals’ Earnings Call: Optimism Amid Challenges
- Lexicon Pharmaceuticals Files Prospectus for Stock Sale
- Lexicon reports Q3 EPS (4c), consensus (7c)